Taylor Beth
Chief Financial Officer at NOTV; VP Finance & Chief Acctg Offcr at ENDOCYTE INC
- Sold, on record
- $300k
- Dollars the filings state
- Form 4 sales
- 6
- Latest Feb 17, 2026
- Form 144 notices
- 0
- Proposed sales
- Quarters with a sale
- 2 of the last 8
- 3 days with a sale in that time
- Companies
- 2
- Filed as an executive or holder
Companies
- NOTVInotiv, Inc.Chief Financial Officer
- ENDOCYTE INCVP Finance & Chief Acctg Offcr
Sales by reason
1
Routine
3
Plan not stated
2
No plan
0
Unusual
Form 4 sales per year, every sale on record.
Sales by company
- ENDOCYTE INC15,199 shares
- NOTV9,312 shares
Shares sold, every Form 4 sale on record.
Timeline
- Feb 17, 2026Routine
Sold 1.9% of their holdings
$8382,888 shares at $0.29
- Feb 18, 2025No plan
Sold 3.9% of their holdings
$18k4,370 shares at $4.01
- Jan 31, 2025No plan
Sold 1.8% of their holdings
$9k2,054 shares at $4.47
- Oct 5, 2018Plan not stated
Sold 11.1% of their holdings
$109k7,022 shares at $15.56
- Aug 28, 2018Plan not stated
Sold 11.1% of their holdings
$158k7,892 shares at $20.00
- Aug 20, 2018Plan not stated
Sold 0.4% of their holdings
$5k285 shares at $18.20
6 of 6
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jul 19, 2026 | Jul 20, 2026 | NOTV | Chief Financial Officer | Other | 139,616 | 0 | SEC | ||
| Jun 18, 2026 | Jun 23, 2026 | NOTV | Chief Financial Officer | Withheld for tax | 5,864 | $0.0200 | $117 | 139,616 | SEC |
| Feb 17, 2026 | Feb 19, 2026 | NOTV | Chief Financial Officer | Sold | 2,888 | $0.29 | $838 | 145,480 | SEC |
| Mar 14, 2025 | Mar 18, 2025 | NOTV | Chief Financial Officer | Awarded | 40,000 | 148,368 | SEC | ||
| Feb 21, 2025 | Feb 25, 2025 | NOTV | Chief Financial Officer | AwardedEmployee Stock Option (right to buy) | 6,500 | 6,500 | SEC | ||
| Feb 18, 2025 | Feb 20, 2025 | NOTV | Chief Financial Officer | Sold | 4,370 | $4.01 | $18k | 108,368 | SEC |
| Jan 31, 2025 | Feb 4, 2025 | NOTV | Chief Financial Officer | Sold | 2,054 | $4.47 | $9k | 112,738 | SEC |
| Aug 10, 2024 | Aug 14, 2024 | NOTV | Chief Financial Officer | AwardedEmployee Stock Option (right to buy) | 20,000 | 20,000 | SEC | ||
| Aug 10, 2024 | Aug 14, 2024 | NOTV | Chief Financial Officer | Awarded | 20,000 | 114,792 | SEC | ||
| Dec 15, 2023 | Dec 15, 2023 | NOTV | Chief Financial Officer | AwardedEmployee Stock Option (right to buy) | 6,250 | 6,250 | SEC | ||
| Feb 17, 2023 | Feb 21, 2023 | NOTV | Chief Financial Officer | Awarded | 5,000 | 94,792 | SEC | ||
| Jan 18, 2023 | Jan 20, 2023 | NOTV | Chief Financial Officer | Awarded | 5,917 | 89,792 | SEC | ||
| Feb 18, 2022 | Feb 22, 2022 | NOTV | VP- Finance & CFO | Bought | 5,000 | $23.07 | $115k | 83,875 | SEC |
| Feb 15, 2022 | Feb 17, 2022 | NOTV | VP- Finance & CFO | Awarded | 40,000 | 78,875 | SEC | ||
| Dec 17, 2021 | Dec 20, 2021 | NOTV | VP- Finance & CFO | Awarded | 214 | 38,875 | SEC | ||
| Oct 22, 2021 | Oct 26, 2021 | NOTV | VP- Finance & CFO | Awarded | 1,332 | 38,661 | SEC | ||
| May 13, 2021 | May 17, 2021 | NOTV | VP- Finance & CFO | Bought | 2,154 | $23.14 | $50k | 37,329 | SEC |
| May 7, 2021 | May 11, 2021 | NOTV | VP- Finance & CFO | Awarded | 880 | 35,175 | SEC | ||
| Mar 5, 2021 | Mar 5, 2021 | NOTV | VP- Finance & CFO | Bought | 5,000 | $17.70 | $89k | 34,295 | SEC |
| Dec 2, 2020 | Dec 4, 2020 | NOTV | VP- Finance & CFO | Awarded | 5,995 | 29,295 | SEC | ||
| Jun 10, 2020 | Jun 11, 2020 | NOTV | VP- Finance & CFO | Awarded | 10,000 | 23,300 | SEC | ||
| May 21, 2020 | May 21, 2020 | NOTV | VP- Finance & CFO | Bought | 13,300 | $4.43 | $59k | 13,300 | SEC |
| Dec 21, 2018 | Dec 21, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Off | Returned to the companyStock Option (right to buy) | 100,261 | $18.55 | $1.9M | 0 | SEC |
| Dec 21, 2018 | Dec 21, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Off | Returned to the company | 99,509 | $24.00 | $2.4M | 0 | SEC |
| Dec 19, 2018 | Dec 19, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Gift | 8,186 | 1,250 | SEC | ||
| Dec 17, 2018 | Dec 19, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Exercised or settledStock option (right to buy) | 48,854 | 15,000 | SEC | ||
| Dec 17, 2018 | Dec 19, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Exercised options | 48,854 | $4.31 | $211k | 105,195 | SEC |
| Oct 5, 2018 | Oct 9, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Sold | 7,022 | $15.56 | $109k | 56,341 | SEC |
| Aug 28, 2018 | Aug 29, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Sold | 7,892 | $20.00 | $158k | 63,363 | SEC |
| Aug 20, 2018 | Aug 22, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Sold | 285 | $18.20 | $5k | 71,255 | SEC |
| Feb 8, 2018 | Feb 8, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | AwardedStock Option (right to buy) | 25,000 | 25,000 | SEC | ||
| Feb 8, 2018 | Feb 8, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Awarded | 12,500 | 71,540 | SEC | ||
| Feb 6, 2018 | Feb 8, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Withheld for tax | 484 | $3.00 | $1k | 59,040 | SEC |
| Feb 4, 2018 | Feb 6, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Withheld for tax | 1,759 | $3.12 | $5k | 59,524 | SEC |
| Oct 4, 2017 | Oct 6, 2017 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Awarded | 30,000 | 61,283 | SEC | ||
| Feb 2, 2017 | Feb 3, 2017 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | AwardedStock Option (right to buy) | 20,000 | 20,000 | SEC | ||
| Feb 2, 2017 | Feb 3, 2017 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Awarded | 10,000 | 31,283 | SEC | ||
| Aug 18, 2016 | Aug 22, 2016 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | AwardedStock Option (right to buy) | 22,500 | 22,500 | SEC | ||
| Aug 18, 2016 | Aug 22, 2016 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Awarded | 3,750 | 21,283 | SEC | ||
| Feb 6, 2016 | Feb 8, 2016 | ENDOCYTE INC | Corporate Controller | Withheld for tax | 525 | $3.02 | $2k | 16,482 | SEC |
| Feb 4, 2016 | Feb 8, 2016 | ENDOCYTE INC | Corporate Controller | AwardedStock Option (right to buy) | 7,500 | 7,500 | SEC | ||
| Feb 4, 2016 | Feb 8, 2016 | ENDOCYTE INC | Corporate Controller | Awarded | 3,750 | 17,007 | SEC | ||
| Feb 6, 2015 | Feb 6, 2015 | ENDOCYTE INC | Corporate Controller | Withheld for tax | 525 | $5.14 | $3k | 11,627 | SEC |
| Feb 4, 2015 | Feb 6, 2015 | ENDOCYTE INC | Corporate Controller | AwardedStock Option (right to buy) | 9,000 | 9,000 | SEC | ||
| Feb 4, 2015 | Feb 6, 2015 | ENDOCYTE INC | Corporate Controller | Awarded | 4,500 | 12,152 | SEC | ||
| Feb 6, 2014 | Feb 10, 2014 | ENDOCYTE INC | Corporate Controller | AwardedStock Option (right to buy) | 10,850 | 10,850 | SEC | ||
| Feb 6, 2014 | Feb 10, 2014 | ENDOCYTE INC | Corporate Controller | Awarded | 5,425 | 7,147 | SEC | ||
| Feb 19, 2013 | Feb 21, 2013 | ENDOCYTE INC | Corporate Controller | AwardedStock Option (right to buy) | 14,362 | 14,362 | SEC | ||
| Feb 29, 2012 | Mar 2, 2012 | ENDOCYTE INC | Corporate Controller | AwardedStock Option (right to buy) | 16,073 | 16,073 | SEC |
Sales and notices (6)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | Feb 19, 2026 | NOTV | Chief Financial Officer | Form 4 sale | 2,888 | $838 | 1.9% | Routine | SEC |
| Feb 18, 2025 | Feb 20, 2025 | NOTV | Chief Financial Officer | Form 4 sale | 4,370 | $18k | 3.9% | No plan | SEC |
| Jan 31, 2025 | Feb 4, 2025 | NOTV | Chief Financial Officer | Form 4 sale | 2,054 | $9k | 1.8% | No plan | SEC |
| Oct 5, 2018 | Oct 9, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Form 4 sale | 7,022 | $109k | 11.1% | Plan not stated | SEC |
| Aug 28, 2018 | Aug 29, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Form 4 sale | 7,892 | $158k | 11.1% | Plan not stated | SEC |
| Aug 20, 2018 | Aug 22, 2018 | ENDOCYTE INC | VP Finance & Chief Acctg Offcr | Form 4 sale | 285 | $5k | 0.4% | Plan not stated | SEC |